Abstract
Background: Hashimoto’s thyroiditis (HT) is characterized by lymphocytic infiltration of the thyroid parenchyma, which ultimately leads to tissue destruction and loss of function. Caveolin-1 (Cav-1) is an essential structural constituent of lipid rafts in the plasma membrane of cells and is reported to be significantly reduced in thyrocytes from HT patients. However, the mechanism of Cav-1 involvement in HT pathogenesis is still largely unclear.
Methods: Cav-1 expression in thyroid tissues from HT patients and euthyroid nodular goiter tissues was detected by immunohistochemistry staining. Cav-1 knockdown and overexpression were constructed by lentiviral transfection in the human thyroid follicular epithelial cell (TFC) line of Nthy-ori 3-1. The mRNA expression levels of chemokines in TFCs were determined by quantitative real-time PCR (qPCR). Cav-1 and peroxisome proliferator-activated receptor gamma (PPARγ) levels were analysed by qPCR and Western blot analysis. The migration ability of peripheral blood mononuclear cells (PBMCs) was detected by the Transwell assay.
Results: In this study, Cav-1 and PPARγ expression was reduced in the thyroid tissues from HT patients. In vitro experiments showed that the expressions of chemokine (C-C motif) ligand 5 (CCL5) and migration of PBMCs were markedly increased, while the level of PPARγ was significantly decreased after the lentivirus-mediated knockdown of Cav-1 in Nthy-ori 3-1 cells. Interestingly, pioglitazone, a PPARγ agonist, not only upregulated PPARγ and Cav-1 proteins significantly, but also effectively reversed the Cav-1-knockdown-induced upregulation of CCL5 in Nthy-ori 3-1 cells and reduced the infiltration of lymphocytes.
Conclusion: The inhibition of Cav-1 upregulated the CCL5 expression and downregulated the PPARγ expression in TFC while pioglitazone, a PPARγ agonist, reversed the detrimental consequence. This outcome might be a potential target for the treatment of lymphocyte infiltration into the thyroid gland and HT development.
Keywords: Hashimoto’s thyroiditis, Cav-1, Chemokine, CCL5, PPARγ, Pioglitazone
[http://dx.doi.org/10.1016/j.autrev.2014.10.016] [PMID: 25461470]
[http://dx.doi.org/10.1210/jc.2008-2291] [PMID: 19494161]
[http://dx.doi.org/10.1007/s12020-015-0631-9] [PMID: 25994301]
[http://dx.doi.org/10.1530/eje.0.1480001] [PMID: 12534350]
[http://dx.doi.org/10.1186/1742-6413-4-10] [PMID: 17470291]
[http://dx.doi.org/10.4103/0970-9371.188055] [PMID: 27756987]
[http://dx.doi.org/10.7314/APJCP.2013.14.4.2295] [PMID: 23725130]
[PMID: 15816560]
[http://dx.doi.org/10.1210/jc.2007-0660] [PMID: 17666482]
[http://dx.doi.org/10.1210/jc.2013-3469] [PMID: 24476075]
[http://dx.doi.org/10.1152/ajpendo.90784.2008] [PMID: 19435853]
[http://dx.doi.org/10.1507/endocrj.EJ18-0003] [PMID: 29877208]
[http://dx.doi.org/10.1016/S1074-7613(00)80165-X] [PMID: 10714678]
[http://dx.doi.org/10.1016/j.yjmcc.2018.01.016] [PMID: 29374556]
[http://dx.doi.org/10.1089/thy.2007.0267] [PMID: 17910527]
[http://dx.doi.org/10.1210/jcem.86.10.7953] [PMID: 11600578]
[http://dx.doi.org/10.1046/j.1365-2265.2003.01824.x] [PMID: 12864798]
[http://dx.doi.org/10.7150/ijbs.10666] [PMID: 25798057]
[http://dx.doi.org/10.1016/j.jaut.2016.07.008] [PMID: 27448770]
[http://dx.doi.org/10.3389/fimmu.2018.00096] [PMID: 29434604]
[http://dx.doi.org/10.1210/jc.2005-1475] [PMID: 16234302]
[http://dx.doi.org/10.1089/thy.2015.0625] [PMID: 27324467]
[http://dx.doi.org/10.21873/cgp.20018] [PMID: 28031237]
[http://dx.doi.org/10.1038/bjc.1989.387] [PMID: 2557880]
[http://dx.doi.org/10.1038/nrc1254] [PMID: 14708026]
[http://dx.doi.org/10.1186/ar3788] [PMID: 22455954]
[http://dx.doi.org/10.1128/MCB.01421-10] [PMID: 21690289]
[http://dx.doi.org/10.2174/1872214808666140623114315] [PMID: 24953644]
[http://dx.doi.org/10.1016/j.imbio.2012.08.267] [PMID: 22944249]
[http://dx.doi.org/10.1155/2010/325183] [PMID: 20981297]
[http://dx.doi.org/10.1016/j.imbio.2012.05.016] [PMID: 22878044]
[http://dx.doi.org/10.1155/2015/979167] [PMID: 26000316]
[http://dx.doi.org/10.1159/000078438] [PMID: 15249726]
[http://dx.doi.org/10.1016/S0960-5428(97)00027-7] [PMID: 9183517]
[http://dx.doi.org/10.1126/science.275.5302.960] [PMID: 9020075]
[http://dx.doi.org/10.1093/carcin/bgt142] [PMID: 23640045]
[http://dx.doi.org/10.1093/cvr/cvq075] [PMID: 20202978]
[http://dx.doi.org/10.4161/cc.10.11.15674] [PMID: 21566463]
[http://dx.doi.org/10.1016/S0960-9822(06)00181-3] [PMID: 9197234]
[http://dx.doi.org/10.1016/S1074-7613(00)80165-X] [PMID: 10714678]
[http://dx.doi.org/10.1055/s-0032-1308973] [PMID: 22473756]
[http://dx.doi.org/10.1016/0092-8674(94)90006-X] [PMID: 8001151]
[http://dx.doi.org/10.1016/S1097-2765(00)80211-7] [PMID: 10549292]
[http://dx.doi.org/10.1038/47254] [PMID: 10622252]
[http://dx.doi.org/10.1016/j.cell.2005.11.026] [PMID: 16360030]
[http://dx.doi.org/10.1194/jlr.M400049-JLR200] [PMID: 15314095]
[PMID: 18507034]
[http://dx.doi.org/10.1093/carcin/bgn103] [PMID: 18460448]
[http://dx.doi.org/10.1038/sj.onc.1206625] [PMID: 12813462]
![Wayfinder Image](/images/wayfinder.jpg)